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Background & Aims:Mesenchymal stromal cell (MSC) infusion
could be a means to establish tolerance in solid organ recipients.
The aim of this prospective, controlled, phase I study was to eval-
uate the feasibility, safety and tolerability of a single infusion of
MSCs in liver transplant recipients.
Methods: Ten liver transplant recipients under standard
immunosuppression received 1.5–3 ! 106/kg third-party unre-
lated MSCs on postoperative day 3 ± 2, and were prospectively
compared to a control group of ten liver transplant recipients.
As primary endpoints, MSC infusion toxicity was evaluated, and
infectious and cancerous complications were prospectively
recorded until month 12 in both groups. As secondary endpoints,
rejection rate, month-6 graft biopsies, and peripheral blood lym-
phocyte phenotyping were compared. Progressive immunosup-
pression weaning was attempted from month 6 to 12 in MSC
recipients.
Results: No variation in vital parameters or cytokine release syn-
drome could be detected during and after MSC infusion. No
patient developed impairment of organ functions (including liver
graft function) following MSC infusion. No increased rate of
opportunistic infection or de novo cancer was detected. As sec-
ondary endpoints, there was no difference in overall rates of
rejection or graft survival. Month-6 biopsies did not demonstrate
a difference between groups in the evaluation of rejection accord-
ing to the Banff criteria, in the fibrosis score or in immunohisto-
chemistry (including Tregs). No difference in peripheral blood
lymphocyte typing could be detected. The immunosuppression
weaning in MSC recipients was not successful.
Conclusions: No side effect of MSC infusion at day 3 after liver
transplant could be detected, but this infusion did not promote
tolerance. This study opens the way for further MSC or Treg-
based trials in liver transplant recipients.
Lay summary: Therapy with mesenchymal stromal cells (MSCs)
has been proposed as a means to improve results of solid organ
transplantation. One of the potential MSC role could be to induce
tolerance after liver transplantation, i.e. allowing the cessation of
several medications with severe side effects. This study is the
first-in-man use of MSC therapy in ten liver transplant recipients.
This study did not show toxicity after a single MSC infusion but it
was not sufficient to allow withdrawal of immunosuppression.
Clinical trial registration number: Eudract: # 2011-001822-81,
ClinicalTrials.gov: # NCT 01429038.
! 2017 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Liver transplantation (LT) has become the gold standard treat-
ment of many hepatic end-stage diseases. Long-term graft and
patient survivals are now common after LT, but recipients are still
subjected to life-long immunosuppression, which impairs
quality of life and might reduce survival by promoting cancer
development or by increasing the risks for infection, kidney
function impairment and cardiovascular diseases. Therefore,
there is a need for improvement in the immunosuppressive pro-
tocols after LT. Finding a way to establish donor-specific
immunological tolerance without the need for non-specific
immunosuppression remains one of the major goals in transplan-
tation medicine [1].
Mesenchymal stromal cells (MSCs) are multipotent progeni-
tors within the bone marrow, capable of differentiating into var-
ious cells and tissues, such as chondrocytes, osteoblasts and
adipocytes [2]. MSCs can be isolated after ex vivo culture of the
adherent mononuclear bone marrow cell fraction. In addition to
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! Abstract — Intracranial hypertension leading to brain
stem herniation is a major cause of death in fulminant
hepatic failure (FHF). Mannitol, barbiturates, and hyper-
ventilation have been used to treat brain swelling, but most
patients are either refractory to medical management or
cannot be treated because of concurrent medical problems
or side effects. In this study, we examined whether alloge-
neic hepatocellular transplantation may prevent develop-
ment of intracranial hypertension in pigs with experimen-
tally induced liver failure. Of the two preparations tested—
total hepatectomy (n ! 47), and liver devascularization
(n ! 16)—only pigs with liver ischemia developed brain
edema provided, however, that animals were maintained
normothermic throughout the postoperative period. This
model was then used in transplantation studies, in which six
pigs received intrasplenic injection of allogeneic hepato-
cytes (2.5" 109 cells/pig) and 3 days later acute liver failure
was induced. In both models (anhepatic state, liver devas-
cularization), pigs allowed to become hypothermic had
significantly longer survival compared to those maintained
normothermic. Normothermic pigs with liver ischemia had,
at all time points studied, ICP greater than 20 mmHg. Pigs
that received hepatocellular transplants had ICP below 15
mmHg until death; at the same time, cerebral perfusion
pressure (CPP) in transplanted pigs was consistently higher
than in controls (45 # 11 mmHg vs. 16 # 18 mmHg; p <
0.05). Spleens of transplanted pigs contained clusters of
viable hepatocytes (hematoxylin-eosin, CAM 5.2). It was
concluded that removal of the liver does not result in
intracranial hypertension; hypothermia prolongs survival
time in both anhepatic pigs and pigs with liver devascular-
ization, and intrasplenic transplantation of allogeneic hepa-
tocytes prevents development of intracranial hypertension
in pigs with acute ischemic liver failure. © 1998 Elsevier
Science Inc.
! Keywords — Hepatocyte; Transplantation; Fulminant
hepatic failure; Intracranial pressure.
INTRODUCTION
Intracranial hypertension, secondary to brain edema, is
the most common cause of brain injury and death in
patients with FHF (13,24). It is life-threatening, because
it may cause (a) brain stem herniation, (b) compression
of the posterior cerebral artery leading to infarction, (c)
obstructive hydrocephalus due to cerebral aqueduct and
subarachnoid space compression, and (d) brain stem
compression resulting in brain stem ischemia, hemor-
rhage, and death. Additionally, intracranial hypertension
may cause a significant decrease in CPP and cerebral
blood flow, and thus aggravate cerebral ischemia or
infarction resulting in major neurological deficits.
The pathogenesis of intracranial hypertension is not
fully understood. At present, both vasogenic (hypoxic)
and cytotoxic factors have been etiologically implicated
(6,11,33,34). Mannitol, barbiturates, and hyperventila-
tion have been used in this setting, but most patients are
either refractory to medical management or cannot be
treated because of related complications (e.g., renal
failure) or side effects (9,16,22). Orthotopic liver trans-
plantation (OLT) remains the only definitive treatment
for FHF and its neurologic complications. However,
severe neurologic dysfunction precludes many FHF pa-
tients from being listed for a transplant. Furthermore, of
those listed for urgent OLT (United Network for Organ
ACCEPTED 4/9/98.
1Correspondence should be addressed to: Jacek Rozga,
M.D., Ph.D., Liver Support Research Laboratory, Department
of Surgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd.,
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•  Source of hepatocytes (human, animal, 
tumor lines) 
•  Culture and differentiation 
•  Site of injection 
•  Rejection (IS?) 
•  Monitoring 
Stem cells 
•  Cells that can differentiate into other types 
of cells and can also divide in-self renewal 
to produce more stem-cells 
•  Adult stem cells act as repair system of 
the body 
Bone Marrow stem cells 
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Granulocyte colony-stimulating factor and autologous 
CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): 
an open-label, randomised, controlled phase 2 trial
Philip Noel Newsome, Richard Fox, Andrew L King, Darren Barton, Nwe-Ni Than, Joanna Moore, Christopher Corbett, Sarah Townsend, 
James Thomas, Kathy Guo, Diana Hull, Heather A Beard, Jacqui Thompson, Anne Atkinson, Carol Bienek, Neil McGowan, Neil Guha, 
John Campbell, Dan Hollyman, Deborah Stocken, Christina Yap, Stuart John Forbes
Summary
Background Results of small-scale studies have suggested that stem-cell therapy is safe and eﬀective in patients with 
liver cirrhosis, but no adequately powered randomised controlled trials have been done. We assessed the safety and 
eﬃcacy of granulocyte colony-stimulating factor (G-CSF) and haemopoietic stem-cell infusions in patients with 
liver cirrhosis.
Methods This multicentre, open-label, randomised, controlled phase 2 trial was done in three UK hospitals and 
recruited patients with compensated liver cirrhosis and MELD scores of 11·0–15·5. Patients were randomly assigned 
(1:1:1) to receive standard care (control), treatment with subcutaneous G-CSF (lenograstim) 15 µg/kg for 5 days, or 
treatment with G-CSF for 5 days followed by leukapheresis and intravenous infusion of three doses of CD133-positive 
haemopoietic stem cells (0·2 × 10⁶ cells per kg per infusion). Randomisation was done by Cancer Research UK Clinical 
Trials Unit staﬀ with a minimisation algorithm that stratified by trial site and cause of liver disease. The coprimary 
outcomes were improvement in severity of liver disease (change in MELD) at 3 months and the trend of change in 
MELD score over time. Analyses were done in the modified intention-to-treat population, which included all patients 
who received at least one day of treatment. Safety was assessed on the basis of the treatment received. This trial was 
registered at Current Controlled Trials on Nov 18, 2009; ISRCTN, number 91288089; and the European Clinical Trials 
Database, number 2009-010335-41.
Findings Between May 18, 2010, and Feb 26, 2015, 27 patients were randomly assigned to the standard care, 26 to the 
G-CSF group, and 28 to the G-CSF plus stem-cell infusion group. Median change in MELD from day 0 to 90 was 
–0·5 (IQR –1·5 to 1·1) in the standard care group, –0·5 (–1·7 to 0·5) in the G-CSF group, and –0·5 (–1·3 to 1·0) in 
the G-CSF plus stem-cell infusion group. We found no evidence of diﬀerences between the treatment groups and 
control group in the trends of MELD change over time (p=0·55 for the G-CSF group vs standard care and p=0·75 for 
the G-CSF plus stem-cell infusion group vs standard care). Serious adverse events were more frequent the in G-CSF 
and stem-cell infusion group (12 [43%] patients) than in the G-CSF (three [11%] patients) and standard care (three [12%] 
patients) groups. The most common serious adverse events were ascites (two patients in the G-CSF group and 
two patients in the G-CSF plus stem-cell infusion group, one of whom was admitted to hospital with ascites twice), 
sepsis (four patients in the G-CSF plus stem-cell infusion group), and encephalopathy (three patients in the G-CSF 
plus stem-cell infusion group, one of whom was admitted to hospital with encephalopathy twice). Three patients died, 
including one in the standard care group (variceal bleed) and two in the G-CSF and stem-cell infusion group 
(one myocardial infarction and one progressive liver disease).
Interpretation G-CSF with or without haemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis 
and might be associated with increased frequency of adverse events compared with standard care.
Funding National Institute of Health Research, The Sir Jules Thorn Charitable Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Chronic liver disease is a common cause of death 
globally, the incidence of which is rising due to a 
combination of alcohol consumption, obesity, and viral 
hepatitis.1,2 Although the primary causes of injury, such 
as alcohol or viruses can be removed or treated, patients 
with cirrhosis often still have progression to liver 
decompensation leading to death.3 For such patients, the 
only proven treatment is liver transplantation, but access 
to this approach is limited globally by the shortage of 
donors, sequelae of long-term immunosuppression, and 
high lifelong medical costs.
Promising preclinical data have suggested that 
injections of bone-marrow-derived cells can reduce 
hepatic fibrosis and stimulate liver regeneration, 
thereby improving the synthetic function of the liver,4–6 
Lancet Gastroenterol Hepatol 
2018; 3: 25–36
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Abstract
AIM
To evaluate the long-term efficacy and safety of au-
tologous stem cell transplantation (SCT) for decom-
pensated liver cirrhosis.
METHODS
Consecutive patients with decompensated liver cirrho-
sis were included and assigned into the SCT group 
and non-transplantation (non-SCT) group according to 
whether they received SCT treatment. Patients were 
Ming-Fang Wang, You-Bing Li, Xiao-Juan Gao, Hao-Yang Zhang, Su Lin, Yue-Yong Zhu
Retrospective Cohort Study
Mesenchymal Stromal Cells (ISCT 2006) 
•  bone marrow 
•  umbilical cord 





•  MSC may have an immunosuppressive and/
or immunoregulatory effect 
        MSC are clinically used in GVHD after BM 
Tx 
•  MSC may have an anti-inflammatory effect 
•  MSC may have an effect in organ 
regeneration 
•  MSC may protect from I/R injury 
 
•  Role of MSC in liver diseases and in SOT? 
INFUSION OF THIRD-PARTY MESENCHYMAL STROMAL 
 CELLS (MSC) AFTER KIDNEY OR LIVER 
TRANSPLANTATION:  
A PHASE I-II, OPEN-LABEL, CLINICAL STUDY  
(EudraCT 2011-001822-81 & NCT01429038) 
 
O Detry, M Vandermeulen, MH Delbouille, J Somja, N Bletard, A Briquet, 
C Lechanteur, O Giet, E Baudoux, M Hannon, F Baron, Y Beguin 
 
Dpts of Abdominal Surgery & Transplantation, Pathology, and Hematology 
Laboratory of Cell and Gene Therapy (LTCG)  
 
CHU Liège, GIGA-R, University of Liège, Belgium  
 
Background: MSC in SOT ? 
•  Pulmonary embolism ? 
•  Cytokine-release syndrome ? 
•  Allergy ? 
•  Anti-HLA immunisation ? 
•  Over immunosupression ? 
•  Cancer ? 
•  Graft vascular thrombosis ? 
Objectives 
•  Primary endpoint: feasibility & safety for LT 
recipients - tolerability of infusion 
- infections (bacterial, viral, fungi) 
- cancers (PTLD, others) 
- patient and graft survivals 
 
•  Secondary endpoint 1: immunosuppression 
- rejection rate 
- biopsy 
- blood immune profile 















As of May 1, 2012 
ALLOGENEIC MSC 
BHS transplant clinical network 
6 clinical trials 
Thawing & infusion 
M&M 
•  Cadaveric liver recipients (DBD & DCD) 
•  Classical immunosuppressive 
management 
    
•  Dose: 1.5 to 3.106 MSC/kg 
•  Central IV injection at day 3 +/-2 post Tx  
M&M: liver 1 
•  Liver transplantation  
- 2 groups:   -10 MSC +: MSC group 
        -10 MSC -: Control group 
  
- prospective, no randomisation, unblinded 
- regular immunosupression (TAC-MMF) 
- protocol biopsy at month 6 in both groups 
- follow-up of one year completed for all patients 
 
•  MSC group:  
- tapering of TAC from month 6 to 9, then biopsy 
- tapering MMF from month 9 to 12  
M&M 
M&M 
•  Blood: FACS, Tregs, Ig, anti-HLA 
 
•  Biopsies: 
- Histology  
- Immunohistology banking of serum & 
biopsies 
Liver recipients 
MSC+ (n=10) MSC- (n=10) P 
Age (years) 62.5 (47-74) 58 (52-69) 0.516 
Male/Female  8/2 7/3 1 










NASH 3 0 
HCC 2 5 
Median (Ranges) or n  (Mann Whitney or Fischer test) 
Liver donors & Transplantations 
MSC+ group (n=10) Control group 
(n=10) 
P 
Age (years) 57 (17-77) 54 (18-79) 0.985 
Male/Female  4/6 6/4 0.656 
CPR (Y/N) 4/6 3/7 1 
Donor type (DBD/DCD) 4/6 5/5 1 
BMI (kg/m2) 24 (21-31) 25 (22-29) 0.510 
Intensive care stay (days) 4 (1-75) 6.5 (2-29) 0.401 
Urinary output (mL/h) 82 (7-160) 127.5 (47-357) 0.096 
Pressors (Y/N) 5/5 6/4 1 
Na (mmol/L) 144 (133-155) 144.5 (141-160) 0.445 
Total bilirubin (mg/dL) 0.35 (0.30-1.59) 0.32 (0.15-0.85) 0.668 
AST (U/L) 38 (23-190) 48.5 (26-91) 0.615 
















 Median (Ranges) or n  (Mann Whitney or Fischer test) 
MSC injection in LT recipients 
Per protocol Study (Median) (IQR; Ranges) 
MSC Injection day day 3 +/- 2 3 (3-3.25; 2-5) 
Dose MSC (106/kg) 1.5-3 2.1 (2.0-2.4; 1.9-2.7) 
Injection volume (ml) 342 (322-469; 306-614) 
Injection duration (min) 25 (16.2-40; 11-60) 
Median (IQR; Ranges) 
Infusional toxicity 







36.3 (35-36.9) 36.2 (35.5-37) 0.87 
Mean PA (mmHg) 103.3 
(87-124) 
107 (84-119.5) 106 (94-115) 0.83 
Heart rate (per min) 81 (65-102) 82.5 (65-102) 80.5 (68-101) 0.17 
NI O2 saturation 99 (93-100) 100 (92-100) 97.5 (93-100) 0.67 
Median (Ranges) (Friedman test & ANOVA) 
-  No hepatic artery or portal vein thrombosis 
-  No sign of pulmonary embolism or post infusional intubation 
-  No anaphylactic reaction, no skin reaction 
 
Infectious complications 





(n = 9) 
P 
Overall 2 6 0.06 
Fungal 0 0 
Viral CMV disease 0 0 
HSV 2 0 
VZV 0 1 
Bacterial Wound 0 1 
Urinary 0 2 
Sinusitis 0 1 
Pulmonary 0 1 
Cancer (6-month follow-up) 
n (Chi square) 
MSC group (n=10) Control group (n = 9) P 
Overall 1 0 >0.99 
de novo 0 0 
HCC recurrence 1 0 
Follow-up at 6 months 
median (Ranges) 
MSC group (n=10) Control group (n = 9) P 
Banff 3 (0-6) 4 (0-7) 0.21 
Fibrosis 1 (0-2) 1 (0-3) 0.48 
Month-6 graft biopsies 
-  No rejection in either groups 
-  One death in the control group (hepatic artery fistula) 
median (Ranges) 
MSC group (n=10) Control group (n = 
9) 
P 
total bilirubin (mg/L) 10.2 (4.6-26.8) 8.3 (3.7-20.7) 0.21 
AST (U/L) 28.5 (19-101) 46 (30-105) 0.16 
Alcaline Ph (U/L) 140 (43-475) 256 (172-590) 0.04 
GGT (U/L) 218 (29-626) 368 (172-760) 0.24 
INR 1.14 (1-1.21) 1.06 (1-1.26) 0.16 
creatinine (mg/L) 11.55 (5.7-36) 8.9 (5.9 – 16.9) 0.32 
CRP (mg/L) 32.8 (8.4-50.1) 24.6 (12.8-144.3) 0.82 
tacrolimus (µg/L) 7.1 (3.1-9) 9 (2.1-11.7) 0.12 
Blood tests Day 7 
median (Ranges) 
MSC group (n=10) Control group (n = 
9) 
P 
total bilirubin (mg/L) 5.6 (3.4-11.6) 4.6 (1.3-7.5) 0.34 
AST (U/L) 18 (11-51) 16 (9-61) 0.48 
Alcaline Ph (U/L) 137.5 (53-554) 144 (103-857) 0.43 
GGT (U/L) 101 (26-596) 112 (42-690) 0.82 
INR 1.15 (0.97-1.26) 1.08 (1-1.19) 0.53 
creatinine (mg/L) 16.2 (5.3-24.4) 14.1 (8.2-27.6) 0.45 
CRP (mg/L) 12.9 (4.8-62.2) 17.2 (3.5-73) 0.94 
tacrolimus (µg/L) 8.1 (2.4-10) 8 (5-16.3) 0.51 
Blood tests Month  1 
median (Ranges) 
MSC group (n=10) Control group (n = 
9) 
P 
total bilirubin (mg/L) 4.8 (3-19.8) 4.3 (2.3-7.5) 0.34 
AST (U/L) 20 (14-31) 20 (11-58) 0.79 
Alcaline Ph (U/L) 101.5 (56-1461) 119 (86-570) 0.54 
GGT (U/L) 58.5 (15-695) 49 (14-332) 0.76 
INR 1.1 (0.95-1.29) 1.13 (1.01-1.56) 0.65 
creatinine (mg/L) 12.05 (5-25.7) 13.4 (7-21.7) 0.92 
CRP (mg/L) 3.1 (1-27.6) 6.8 (1.3-23.5) 0.20 
tacrolimus (µg/L) 7.7 (3.7-13) 6.4 (5.2-13.2) 0.61 
Blood tests Month 3 
median (Ranges) 
MSC group (n=10) Control group (n = 
9) 
P 
total bilirubin (mg/L) 6.6 (3.7-25.7) 4.6 (0.43-27) 0.27 
AST (U/L) 25 (15-44) 24 (14-136) 0.64 
Alcaline Ph (U/L) 143.5 (67-1,166) 186 (82-554) 0.26 
GGT (U/L) 81 (22-978) 53 (12-2,064) 0.43 
INR 1.1 (1-1.26) 1.07 (1-1.17) 0.23 
creatinine (mg/L) 11.6 (7.1-18.9) 10.1 (1.28-15.8) 0.30 
CRP (mg/L) 3.5 (0.7-36.5) 5.6 (0.9-151) 0.23 
tacrolimus (µg/L) 4.9 (2.3-9.3) 7.4 (4.9-13) 0.02 
Blood tests Month 6 
median (Ranges) 
MSC group (n=10) Control group (n = 9) P 
CD3 196 (95-334) 162 (93-590) 0.86 
CD4 101 (54-212) 103 (17-496) > 0.99 
CD8 69 (15-196) 85 (12-300) 0.49 
CD68 28.5 (12–75) 40 (15-104) 0.58 
CD1a 1 (0-3) 1 (0-3) 0.83 
CD138 7.5 (4-38) 6 (2-44) 0.50 
CD20 27 (3-95) 28 (10-163) 0.66 
FoxP3 2 (0-16) 4 (0-33) 0.49 
Month-6 graft biopsies 
Follow-up at 1 year 
- Patient and graft survivals at 90% in both groups 
Cancer 
MSC group (n=10) Control group (n = 9) P 
Overall 1 1 >0.99 
de novo 0 0 
HCC recurrence 1 1 
Peripheral Blood Lymphocyte count 
Month 1  MSC group 
(n=10) 
Control (n=9) P 
White blood cells (/µL) 6,630 (3,280-9,700) 5,190 (4,150-10,030) 0.67 
Lymphocytes (/µL) 855 (380-1,690) 940 (300-1,550) 0.92 
CD3 (/µL) 687 (288-1,406) 620 (200-1,336) 0.48 
CD45RA (/µL) 119 (50-557) 147 (48-234) 0.70 
CD45RO (/µL) 373 (179-516) 201 (79 -609) 0.23 
CD3+CD4+ (/µL) 535 230-978) 349 (128-786) 0.30 
CD3+CD56+ (/µL) 27 (1-87) 42 (4-154) 0.35 
CD3+CD8+ (/µL) 115 (49-418) 142 (57-336) 0.76 
CD19 (/µL) 144 (30-286) 99 (38-369) 0.70 
CD56 (/µL) 109 (45-365) 188 (58-618) 0.27 
Peripheral Blood Lymphocyte count 
Month 3  MSC group 
(n=10) 
Control (n=9) P 
White blood cells (/µL) 5,265 (970-8,160) 5,200 (2,470-7,030) 0.39 
Lymphocytes (/µL) 875 (420-1,880) 760 (490-1,760) 0.82 
CD3 (/µL) 767 (352-1,225) 553 (274-1,419) 0.30 
CD45RA (/µL) 123 (51-389) 82 (54-259) 0.58 
CD45RO (/µL) 381 (171-680) 179 (135-765) 0.23 
CD3+CD4+ (/µL) 516 (292-923) 285 (202-976) 0.27 
CD3+CD56+ (/µL) 21 (1-99) 34 (2-197) 0.76 
CD3+CD8+ (/µL) 202 (41-496) 228 (56-362) 0.94 
CD19 (/µL) 93 (34-354) 100 (21-321) 0.76 
CD56 (/µL) 154 (66-331) 119 (59-550) 0.82 
Peripheral Blood Lymphocyte count 
Month 6 MSC group 
(n=10) 
Control (n=9) P 
White blood cells (/µL) 4,815 (4,200-8,150) 5,440 (2,680-11,430) 0.99 
Lymphocytes (/µL) 1,250 (660-2,260) 1,000 (540-1,340) 0.23 
CD3 (/µL) 880 (395-2,098) 592 (342-1,366) 0.27 
CD45RA (/µL) 127 (76-364) 108 (61-298) 0.58 
CD45RO (/µL) 396 (214-615) 267 (156-864) 0.20 
CD3+CD4+ (/µL) 623 (348-728) 359 (224-1,163) 0.20 
CD3+CD56+ (/µL) 31 (1-91) 36 (3-117) 0.54 
CD3+CD8+ (/µL) 238 (38-1,471) 210 (73-345) 0.70 
CD19 (/µL) 99 (25-256) 192 (52-258) 0.27 




















































































































































































Peripheral blood CD4+ T cells 





















































































































































































•  HLA liver recipient 
•  HLA liver donor 
•  HLA MSC donor 
•  CDC 
•  Luminex 
anti - HLA 
•  CDC ≠ Luminex 
•  Control group 
 anti-HLA: liver donor 
 anti-HLA: other – transfusion? 
•  9 MSC + patients underwent MSC 
weaning attempt (first TACRO, then MMF) 
 
•  1 patient was successfully weaned 
•  2 patients were on MMF monotherapy at 
month 9, but did not “tolerate” MMF 
weaning 
•  6 patients had increasing liver tests during 
TACRO weaning  
Phase 2 trial: IS weaning 
Conclusions 
•  Third party MSC infusion is feasable and 
seems safe in LT recipients 
•  Weaning of IS after one single injection of 
MSC in LT patients under TAC-MMF is not 
possible 
 
•  Timing? dose? number? source? IS?  
Present & Future 
•  MSC Lab (Pr F Jouret, Dr M Vandermeulen) 
•  GMP accreditation of the MSC  
•  Complete results of the kidney – MSC trial 
•  Phase 2 trial  
•  Repeated allo MSC infusion in 10 liver transplants 
with tolerogenic IS protocol (basilixumab – 
everolimus – MMF – low dose steroids and 
progressive IS weaning 
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